摘要
[摘要 ] 目的 探究替米沙坦联合川芎嗪治疗早期 2型糖尿病合并高血压的临床疗效。方法 从该院选取 2017年 12月— 2019年 12月接受治疗的 86例 2型糖尿病合并高血压患者作为研究对象，随机分为观察组与对照组，两组患者均为 43例。其中对照组用替米沙坦药物对患者进行治疗 ;观察组在对照组治疗基础上用川穹嗪联合治疗，对比两组患者治疗效果，同时对比治疗后两组间空腹血糖（ FPG）、餐后 2 h血糖（ 2 hPG）、糖化血红蛋白（ HbAlc）、收缩压（ SBP）、舒张压（ DBP）指标水平。结果 两组患者治疗后较治疗前 FPG、 2 hPG、 HbAlc、 SBP、 DBP指标水平均有明显降低，其中观察组优于对照组（ P<0.05） ;治疗过程中，观察组不良反应发生率（ 13.95%）与对照组（ 18.60%）对比差异无统计学意义（ P>0.05）。结论 在早期 2型糖尿病合并高血压治疗中，运用替米沙坦联合川芎嗪治疗对改善患者血压、血脂方面具有积极作用，值得临床推广应用。
[关键词 ] 替米沙坦 ;川芎嗪 ;2型糖尿病 ;高血压
[Abstract] Objective To explore the clinical efficacy of telmisartan combined with ligustrazine in the treatment of early type 2 diabetes mellitus complicated with hypertension. Methods from December 2017 to December 2019, 86 patients with type 2 diabetes complicated with hypertension were randomly divided into observation group and control group, with 43 cases in both groups. The control group was treated with telmisartan; the observation group was treated with Ligustrazine on the basis of the treatment of the control group. The therapeutic effect of the two groups was compared, and the levels of fasting blood glucose (FPG), 2 h postprandial blood glucose (2 HPG), glycosylated blood red egg white (HbAlc), systolic blood pressure (SBP), diastolic blood pressure (DBP) were compared between the two groups after treatment. Results the levels of FPG, 2hPG, HbAlc, SBP and DBP in the two groups after treatment were significantly lower than those before treatment, and the observation group was better than the control group (P < 0.05); during the treatment, the incidence of adverse reactions in the observation group (13.95%) was not significantly different from that in the control group (18.60%) (P > 0.05). Conclusion telmisartan combined with Ligustrazine has a positive effect on improving blood pressure and blood lipid in patients with early type 2 diabetes mellitus complicated with hypertension, which is worthy of clinical application.
出版日期
2020年09月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
